Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome

• Status: Recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate if lymphocyte markers predict response to rituximab among patients with idiopathic nephrotic syndrome

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National University Health System, Singapore
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Age 1-18 years old at the time of diagnosis of nephrotic syndrome

• Steroid-dependent (SDNS) or steroid-resistant nephrotic syndrome (SDNS)

Exclusion Criteria:

• eGFR <60 ml/min per 1.73m2

• infantile onset of nephrotic syndrome

• nephrotic syndrome secondary to chronic infections such as hepatitis B, hepatitis C or human immunodeficiency virus, systemic lupus erythematosus, Henoch-Schönlein purpura, IgA nephropathy, membranoproliferative glomerulonephritis or membranous nephropathy

• current or previous therapy for tuberculosis

• presence of mutations in WT1, NPHS1, NPHS2 and TRPC6.